S1 subunit Archives

The Trend Reduction In COVID-19 Daily Deaths.

30 April 2022

SARS-CoV-2 Was Waving A White Flag By June 2020. Since the onset of the Great Insanity we have been following the COVID-19 mortality rate and total deaths on a daily basis, as mortality rate is ultimately the best measure of infectivity, i.e. the damage to human health that a pathogen can cause. For an explanation […]

What Makes SARS-CoV-2 More Infectious.

12 February 2022

The Role Of The RBM:ACE2 Interface. A little over a year ago, we set out how increased infectiousness meant greater vulnerability, i.e. a new variant may be more infectious but it is also more susceptible to destruction by the innate immune response. The chances are that most people now know what a structural spike protein […]

Why Delta / B1.617.2 Is NOT A Problem.

6 July 2021

Just What Is Different About Delta? B1.617.2/Delta is apparently still spreading. This is unsurprising given that it has been occurring globally for over eight months. At least the WHO has finally applied a nomenclature to the main SARS-CoV-2 variants, adding to the existing PANGO and Nextstrain designations. This validates something we first highlighted four months […]

SARS-COV-2’s Defences Against Detection.

18 May 2021

What Variants Want. Considerable coverage is being given to variant B1.617. This is the ‘Indian’ variant if you use the incorrect basis of giving single country, geographical names to variants that appear globally across multiple variants and are not new, having been in existence for months and in some cases, over a year. As part […]

The ‘Third Wave’ That Has Been Here All Along.

24 March 2021

B1.1.7 v B1.1.28 v B1.351. As we have previously explained, SARS-CoV-2 neither thinks nor acts geographically. Yet the misleading designation of SARS-CoV-2 variants on a geographical basis continues to dominate media coverage and government obsession, with the putative ‘third wave’ being down to either the Brazilian variant or the UK variant dependent upon whether you […]

IgA – Faster, Stronger and More Effective.

11 March 2021

The Star Player On Your Team. Following seroconversion, immumoglobulin A (IgA) istoype is the most frequently created antibody in the immune system. This is principally because it dominates the upper respiratory tract, which is usually the first point of contact between pathogen and human. Therefore, it is needed more frequently than the other isotypes. As […]

Calcifediol (Vitamin D) Is The Most Effective Vaccine.

14 February 2021

Our Position On Calcifediol Is Validated Again. In early July 2020 we identified the importance of vitamin D in respect of SARS-CoV-2, both in terms of systematic vitamin D deficiency leading to increased COVID-19 disease severity & resultant higher mortality rates and the role of vitamin D in providing protective or sterilising immunity. Natural exposure […]

Why The S Protein Is Not The Target You Are Looking For.

11 February 2021

The First Lesson Of Camouflage – Not Being Seen. The majority of vaccines and antivirals both in use and in development as SARS-CoV-2 countermeasures target the structural Spike protein. We have highlighted previously that as the S protein trimers contain the RBDs, the S protein houses the virion’s principal weapon and is therefore the obvious, […]

More Infectious Equals More Vulnerable.

28 January 2021

Infectiousness And Infectivity Are Not The Same. Infectiousness is how easily a pathogen can spread and infectivity is the level of disease severity it can cause. We explained this in more detail earlier this month in response to the UK government’s regular – and one would predicate deliberate – confusion of the two. S-VoC / […]

N501Y Is More Infectious But NOT More Dangerous.

13 January 2021

Infectiousness Or Infectivity. If the government is to be believed, the new killer mutant of death (no, not vaccines minister Zoonotic Gaddafi, the other killer mutant of death known as N501Y) is even more infectious and even more transmissible. Except the government likes to confuse viral infectiousness with disease severity. They are very different. Also, […]